X hits on this document

549 views

0 shares

0 downloads

0 comments

3 / 170

AGENDA

  • On April 1 and 2, 2009, two different new drug applications (NDAs), proposed for the treatment of hyperglycemia in adults with type 2 diabetes mellitus will be discussed.

  • On April 1, 2009, the committee will discuss NDA 22-350, Saxagliptin tablets, Bristol-Myers Squibb.

  • On April 2, 2009, the committee will discuss NDA 22-341, Liraglutide injection, Novo Nordisk, Inc.

FDA Advisory Committee Information Line

  • 1-800-741-8138

(301-443-0572 in the Washington DC area) Code: 3014512536

Contact Information

  • Paul Tran, R.Ph.

Centre for Drug Evaluation and Research (HFD-21) Food and Drug Administration 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, Rm. 1093) Rockville, MD 20857 Phone: 301-827-7001 Fax: 301-827-6776 Email: paul.tran@fda.hhs.gov

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

2

Document info
Document views549
Page views549
Page last viewedSun Dec 11 02:20:26 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments